← Eichor
Condition: Recurrent Melanoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Perioperative Treatment With Tranexamic Acid in Melanoma
Phase 3 · 5 location(s) · University of Aarhus · NCT05899465Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recu
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06660420Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Phase 2 · 1 location(s) · N.N. Petrov National Medical Research Center of Oncology · NCT06229340WoW - Single- vs Two-staged Excisions of Thin Melanoma
NA · 1 location(s) · Vastra Gotaland Region · NCT06363591ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Phase 1/Phase 2 · 21 location(s) · Immatics US, Inc. · NCT03686124A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
Phase N/A · 1 location(s) · Fondazione del Piemonte per l'Oncologia · NCT07469709Palbociclib and Pembrolizumab In Central Nervous System Metastases
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT02896335A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
NA · 2 location(s) · Leiden University Medical Center · NCT06767332Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase 1/Phase 2 · 13 location(s) · Perspective Therapeutics · NCT05655312Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Phase 1/Phase 2 · 3 location(s) · Novelwise Pharmaceutical Corporation · NCT07136181Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Phase 2 · 1 location(s) · University of Utah · NCT06365619Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Phase 2 · 2 location(s) · Brigham and Women's Hospital · NCT04899908
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.